Story · Medicine & Biotech · Health Tech
Computational Pharmacovigilance of Newly Launched Oral GLP-1 Receptor Agonists: Multi-Measure Signal Detection and Temporally Validated Machine Learning on FAERS
1 outlet · first reported by Research Square on
Purpose: Orforglipron and oral semaglutide 25 mg entered the US obesity market in 2026 without post-marketing safety data. This study aimed to detect early adverse-event reporting signals for both agents and to test whether machine-learning models that triage serious reports remain reliable after a… (Research Square)
Coverage, in order
-
Computational Pharmacovigilance of Newly Launched Oral GLP-1 Receptor Agonists: Multi-Measure Signal Detection and Temporally Validated Machine Learning on FAERS
Purpose: Orforglipron and oral semaglutide 25 mg entered the US obesity market in 2026 without post-marketing safety data. This study aimed to detect early adverse-event reporting signals for both agents and to test whether machine-learning models that triage serious reports remain reliable after a…
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.